EXOSOMM

Company Overview

Snapshot

Founded in December 2021 by Prof. Shimon, Yaffa Elbaum-Shiff, and Regina Golan-Gerstl, EXOSOMM operates with 1–10 employees. The company has raised $4.52M across six funding rounds from six investors.

Business overview

EXOSOMM develops bioactive nutritional ingredients derived from natural milk exosomes, targeting the medical food and nutraceutical sectors. The company employs a patented, chemical-free technology to isolate these natural nanoparticles from whey, a byproduct of the cheese-making industry, preserving their active cargo. These milk-derived exosomes act as durable biological carriers for microRNAs, which regulate immune responses and facilitate intercellular communication. EXOSOMM's primary solution focuses on Inflammatory Bowel Diseases (IBD), including Crohn's and Colitis, offering a non-synthetic method to reduce inflammation and extend remission. By upcycling dairy industry byproducts, EXOSOMM provides a sustainable and scalable source of functional ingredients for managing chronic inflammatory and metabolic disorders, offering a food-based alternative to traditional pharmaceutical treatments.

Strategic signal

In April 2025, EXOSOMM was recognized as one of the Top 10 FoodTech World Cup Finalists. This achievement highlights the company's innovative approach in the food technology sector, validating its potential to disrupt the market with its bioactive milk exosome ingredients. For investors, this signals strong industry recognition and potential for future growth and partnerships within the food and health industries.

Company Intelligence Q&A

What is EXOSOMM's core technology?

EXOSOMM utilizes a patented, chemical-free technology to isolate natural milk exosomes from whey, a byproduct of the cheese-making industry. These exosomes function as biological carriers for microRNAs, regulating immune responses and facilitating intercellular communication.

What recognition did EXOSOMM receive in the food tech industry?

In April 2025, EXOSOMM was named one of the Top 10 FoodTech World Cup Finalists, acknowledging its innovative contributions to the food technology sector.

What is EXOSOMM's primary therapeutic focus?

EXOSOMM's flagship solution targets Inflammatory Bowel Diseases (IBD), such as Crohn's and Colitis, aiming to reduce inflammation scores and extend remission periods using non-synthetic methods.